Zura Bio director granted 38,823 stock options

Zura Bio Ltd director Parvinder Thiara reported receiving a share option award covering 38,823 Class A Ordinary Shares.

Rhea-AI Filing Summary

Zura Bio Ltd director Parvinder Thiara reported receiving a share option award covering 38,823 Class A Ordinary Shares. The option, with a conversion or exercise price of $6.36 per share, was granted on January 23, 2026 and is held directly.

The option vests in twelve substantially equal monthly installments over a one-year period starting January 23, 2026. Any remaining unvested portion will vest on the day immediately preceding the next annual meeting of shareholders following the grant date, subject to Thiara’s continued service on each vesting date.

Insider Trade Summary

Grant/Award: 38,823 shares

Grant/Award 1 txn

Insider Thiara Parvinder

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	38,823	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 38,823 contracts (Direct)

Footnotes (1)

1. F1. This option vests in twelve substantially equal monthly installments over a one-year period measured from January 23, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Zura Bio (ZURA) report for Parvinder Thiara?

Zura Bio reported that director Parvinder Thiara received a stock option grant for 38,823 Class A Ordinary Shares. The option was granted on January 23, 2026 and is reported as directly owned following the transaction.

What are the key terms of Parvinder Thiara’s option grant at Zura Bio (ZURA)?

The grant is a Share Option (Right to Buy) for 38,823 Class A Ordinary Shares with a conversion or exercise price of $6.36 per share. The derivative security itself was granted at a price of $0.

How does Thiara’s Zura Bio (ZURA) option vest over time?

The option vests in twelve substantially equal monthly installments over one year starting January 23, 2026. Any remaining unvested portion vests immediately before the next annual shareholder meeting, subject to continued service on each vesting date.

How many derivative securities does Parvinder Thiara hold after this Zura Bio (ZURA) transaction?

Following the reported transaction, Thiara beneficially owns 38,823 derivative securities related to this option grant. These are reported as directly held and correspond to 38,823 underlying Class A Ordinary Shares if fully exercised.

Is Parvinder Thiara a director or officer of Zura Bio (ZURA)?

Parvinder Thiara is reported as a director of Zura Bio Ltd. The filing does not list any officer title and indicates Thiara is not a 10% owner, with the Form 4 filed for a single reporting person.

What service conditions apply to Thiara’s Zura Bio (ZURA) option vesting?

Vesting is explicitly subject to the Reporting Person’s continued service on each vesting date. If Thiara remains in service, monthly vesting occurs, and any remaining unvested options vest just before the next annual shareholder meeting after the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 06:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thiara Parvinder

(Last) (First) (Middle)

C/O ZURA BIO LIMITED

1489 W. WARM SPRINGS RD. #110

(Street)

HENDERSON NV 89014

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zura Bio Ltd [ ZURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$6.36	01/23/2026		A		38,823		(1)	01/23/2036	Class A Ordinary Shares	38,823	$0	38,823	D

Explanation of Responses:

1. This option vests in twelve substantially equal monthly installments over a one-year period measured from January 23, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.

	/s/ Kim Davis, Attorney-in-Fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.